Based on these evidences, STAT3 has been chosen as a target in novel cancer treatment strategies: a drug designed to target STAT3 is AZD9150, called Danvatirsen, a generation 2.5 ASO with a constrained-ethyl group produced by IONISTM in partnership with AstraZeneca (Table 3). This evidence concerns the gene STAT3 and cancer.